"Roche...announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer....The two tests are now available in the US. They will likely be available in other non-CE markets later this year and in countries that accept the CE mark in 2024."